Frazier Management as of Dec. 31, 2021
Portfolio Holdings for Frazier Management
Frazier Management holds 43 positions in its portfolio as reported in the December 2021 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Arcutis Biotherapeutics (ARQT) | 13.5 | $175M | 8.4M | 20.74 | |
| Phathom Pharmaceuticals (PHAT) | 8.8 | $115M | 5.8M | 19.67 | |
| Imago Biosciences | 5.4 | $70M | 3.0M | 23.71 | |
| Syndax Pharmaceuticals (SNDX) | 4.7 | $61M | 2.8M | 21.89 | |
| Gritstone Oncology Ord (GRTS) | 4.6 | $60M | 4.7M | 12.86 | |
| Mirum Pharmaceuticals (MIRM) | 4.4 | $57M | 3.6M | 15.95 | |
| Vaxcyte (PCVX) | 4.2 | $55M | 2.3M | 23.79 | |
| Krystal Biotech (KRYS) | 4.2 | $54M | 771k | 69.95 | |
| Pardes Biosciences | 3.1 | $40M | 2.5M | 16.37 | |
| Crinetics Pharmaceuticals In (CRNX) | 3.0 | $39M | 1.4M | 28.41 | |
| Chinook Therapeutics | 3.0 | $39M | 2.4M | 16.31 | |
| Bicycle Therapeutics Sponsored Ads (BCYC) | 2.6 | $34M | 555k | 60.87 | |
| Iovance Biotherapeutics (IOVA) | 2.6 | $33M | 1.7M | 19.09 | |
| Tarsus Pharmaceuticals (TARS) | 2.5 | $32M | 1.4M | 22.50 | |
| Passage Bio (PASG) | 2.4 | $32M | 5.0M | 6.35 | |
| Anaptysbio Inc Common (ANAB) | 2.4 | $31M | 900k | 34.75 | |
| Iveric Bio | 2.4 | $31M | 1.8M | 16.72 | |
| Miragen Therapeutics (VRDN) | 2.3 | $30M | 1.5M | 19.77 | |
| Sierra Oncology Com New | 2.1 | $28M | 1.3M | 21.74 | |
| Sutro Biopharma (STRO) | 2.0 | $26M | 1.8M | 14.88 | |
| Alpine Immune Sciences | 1.9 | $25M | 1.8M | 13.85 | |
| Silence Therapeutics Ads (SLN) | 1.6 | $21M | 886k | 23.89 | |
| Autolus Therapeutics Spon Ads (AUTL) | 1.5 | $19M | 3.7M | 5.19 | |
| Merus N V (MRUS) | 1.4 | $18M | 559k | 31.80 | |
| Replimune Group (REPL) | 1.4 | $18M | 651k | 27.10 | |
| Tyra Biosciences (TYRA) | 1.4 | $18M | 1.3M | 14.07 | |
| Kalvista Pharmaceuticals (KALV) | 1.3 | $17M | 1.3M | 13.23 | |
| Tricida | 1.3 | $17M | 1.8M | 9.56 | |
| Cogent Biosciences (COGT) | 1.2 | $15M | 1.8M | 8.58 | |
| Frazier Lifesciences Acqu Unit 12/09/2025 | 1.1 | $15M | 1.5M | 9.92 | |
| Arvinas Ord (ARVN) | 1.0 | $14M | 164k | 82.14 | |
| Gracell Biotechnologies Sponsored Ads | 0.8 | $10M | 1.7M | 6.04 | |
| Essa Pharma Com New (EPIX) | 0.6 | $7.7M | 544k | 14.20 | |
| Regenxbio Inc equity us cm (RGNX) | 0.6 | $7.7M | 236k | 32.70 | |
| Avadel Pharmaceuticals Sponsored Adr | 0.6 | $7.7M | 952k | 8.08 | |
| Aclaris Therapeutics (ACRS) | 0.5 | $5.9M | 408k | 14.54 | |
| Molecular Templates | 0.4 | $5.4M | 1.4M | 3.92 | |
| Aptinyx | 0.4 | $5.0M | 1.9M | 2.67 | |
| Immunovant (IMVT) | 0.4 | $5.0M | 586k | 8.52 | |
| Scholar Rock Hldg Corp (SRRK) | 0.3 | $3.9M | 156k | 24.84 | |
| Epizyme | 0.1 | $1.8M | 739k | 2.50 | |
| Allena Pharmaceuticals | 0.1 | $978k | 1.7M | 0.59 | |
| Nabriva Therapeutics SHS | 0.0 | $255k | 426k | 0.60 |
